JP2020054336A - 乾癬性関節炎の診断及び治療 - Google Patents
乾癬性関節炎の診断及び治療 Download PDFInfo
- Publication number
- JP2020054336A JP2020054336A JP2019136489A JP2019136489A JP2020054336A JP 2020054336 A JP2020054336 A JP 2020054336A JP 2019136489 A JP2019136489 A JP 2019136489A JP 2019136489 A JP2019136489 A JP 2019136489A JP 2020054336 A JP2020054336 A JP 2020054336A
- Authority
- JP
- Japan
- Prior art keywords
- mir
- mirna
- psoriatic arthritis
- sample
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000001263 Psoriatic Arthritis Diseases 0.000 title claims abstract description 119
- 208000036824 Psoriatic arthropathy Diseases 0.000 title claims abstract description 119
- 238000011282 treatment Methods 0.000 title claims description 29
- 238000003745 diagnosis Methods 0.000 title description 9
- 108091070501 miRNA Proteins 0.000 claims abstract description 95
- 239000002679 microRNA Substances 0.000 claims abstract description 93
- 230000014509 gene expression Effects 0.000 claims abstract description 84
- 108091073613 miR-941-1 stem-loop Proteins 0.000 claims abstract description 51
- 108091039878 miR-941-2 stem-loop Proteins 0.000 claims abstract description 51
- 108091035558 miR-941-3 stem-loop Proteins 0.000 claims abstract description 51
- 108091031187 miR-941-4 stem-loop Proteins 0.000 claims abstract description 51
- 108091085604 miR-941-5 stem-loop Proteins 0.000 claims abstract description 51
- 108091024530 miR-146a stem-loop Proteins 0.000 claims abstract description 49
- 108091040069 miR-146a-1 stem-loop Proteins 0.000 claims abstract description 49
- 108091081537 miR-146a-2 stem-loop Proteins 0.000 claims abstract description 49
- 108091032392 miR-146a-3 stem-loop Proteins 0.000 claims abstract description 49
- 238000000034 method Methods 0.000 claims abstract description 38
- 238000000338 in vitro Methods 0.000 claims abstract description 3
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims description 61
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims description 61
- 239000000523 sample Substances 0.000 claims description 58
- 210000001616 monocyte Anatomy 0.000 claims description 51
- 210000002997 osteoclast Anatomy 0.000 claims description 24
- 239000003112 inhibitor Substances 0.000 claims description 21
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 8
- 238000003753 real-time PCR Methods 0.000 claims description 5
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims description 2
- 239000002751 oligonucleotide probe Substances 0.000 claims description 2
- 210000000963 osteoblast Anatomy 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 description 19
- 102000039446 nucleic acids Human genes 0.000 description 15
- 108020004707 nucleic acids Proteins 0.000 description 15
- 150000007523 nucleic acids Chemical class 0.000 description 15
- 230000000295 complement effect Effects 0.000 description 14
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 10
- 238000001890 transfection Methods 0.000 description 10
- 230000000875 corresponding effect Effects 0.000 description 9
- 108091033319 polynucleotide Proteins 0.000 description 9
- 102000040430 polynucleotide Human genes 0.000 description 9
- 239000002157 polynucleotide Substances 0.000 description 9
- 108010025832 RANK Ligand Proteins 0.000 description 7
- 102000014128 RANK Ligand Human genes 0.000 description 7
- 238000007481 next generation sequencing Methods 0.000 description 7
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 6
- 210000005087 mononuclear cell Anatomy 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 230000002093 peripheral effect Effects 0.000 description 6
- 230000001185 psoriatic effect Effects 0.000 description 6
- 108700011259 MicroRNAs Proteins 0.000 description 5
- 239000013614 RNA sample Substances 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 206010003246 arthritis Diseases 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 4
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000002493 microarray Methods 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 108091032955 Bacterial small RNA Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 108091081021 Sense strand Proteins 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 239000003435 antirheumatic agent Substances 0.000 description 2
- IMOZEMNVLZVGJZ-QGZVFWFLSA-N apremilast Chemical compound C1=C(OC)C(OCC)=CC([C@@H](CS(C)(=O)=O)N2C(C3=C(NC(C)=O)C=CC=C3C2=O)=O)=C1 IMOZEMNVLZVGJZ-QGZVFWFLSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000002988 disease modifying antirheumatic drug Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical group O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000011325 microbead Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 229960004540 secukinumab Drugs 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001179 synovial fluid Anatomy 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical group CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 229960003824 ustekinumab Drugs 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010023203 Joint destruction Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000031709 Skin Manifestations Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 229960001164 apremilast Drugs 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 238000007621 cluster analysis Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229940010466 cosentyx Drugs 0.000 description 1
- 238000002790 cross-validation Methods 0.000 description 1
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 238000011990 functional testing Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 229960001743 golimumab Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 238000010801 machine learning Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 229940011530 otezla Drugs 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000001303 quality assessment method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 1
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Plant Pathology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
本出願は、2018年7月24日に出願された米国出願第62/702,551号の利益を主張するものであり、この内容は、全体が参照により本明細書に組み込まれる。
研究参加者:乾癬性関節炎の患者(症例)及びPsAのない正常対照(NC)における各miRNAの発現を調べるために、症例対照研究を実施した。
PsA患者のCD14+単球由来の破骨細胞に対するmiR−941阻害剤及びmiR−146a−5p阻害剤の効果のインビトロ評価を実施した。
(1)miRNAトランスフェクションなし:破骨細胞に分化するために、CD14+単球を9日間、3日ごとにTNF−α及びRANKLとともに培養した。
(2)陰性対照mRNAトランスフェクション:CD14+単球に陰性対照miRNA(配列番号3)を6時間トランスフェクトし、その後9日間3日ごとにTNF−α及びRANKLとともに培養して破骨細胞に分化させた。
(3)miR−941阻害剤トランスフェクション:CD14+単球にmiR−941阻害剤(配列番号4)を6時間トランスフェクトし、次いで破骨細胞に分化させるために9日間、3日ごとにTNF−αおよびRANKLとともに培養した。
(4)miR−146a−5p阻害剤トランスフェクション:CD14+単球にmiR−146a−5p阻害剤(配列番号5)を6時間トランスフェクトし、次いで破骨細胞に分化するために9日間、3日ごとにTNF−αおよびRANKLとともに培養した。
さらに、40人の健康な正常対照(NC)、40人の関節炎のない乾癬患者(PsO)、及び40人の乾癬性関節炎患者(PsA)におけるmiR146a−5pとmiR941の発現を調べるために含まれるケースコントロール研究を行われた。
Claims (11)
- 被験者のサンプル中にmiR−146a−5p及びmiR−941からなる群から選択される少なくとも一つのmiRNAの発現レベルを測定するステップとを含み、
前記サンプル中の前記少なくとも一つのmiRNAの発現レベルが、乾癬性関節炎のないサンプル中の少なくとも一つの対応のmiRNAの発現レベルより高い場合、前記被験者が乾癬性関節炎を罹患または発症リスクが存在することの指標となることを特徴とする、被験者の乾癬性関節炎(psoriatic arthritis)を検出または発症リスクを予測するためのインビトロ方法。 - 前記miRNAの発現レベルは、リアルタイムPCR(real−time PCR)によって検出されることを特徴とする、請求項1に記載の方法。
- 前記miRNAの発現レベルは、配列番号1または配列番号2と少なくとも90%同一のオリゴヌクレオチドプローブによって検出されることを特徴とする、請求項に1記載の方法。
- 前記サンプルはCD14+単球(monocyte)であることを特徴とする、請求項1に記載の方法。
- 前記サンプルは破骨細胞(osteoclast)であることを特徴とする、請求項1に記載の方法。
- 前記破骨細胞はCD14+単球に由来するものであることを特徴とする、請求項5に記載の方法。
- 配列番号1と少なくとも90%同一のmiR−146a−5p阻害剤、または配列番号2と少なくとも90%同一のmiR−941阻害剤を投与するステップを含むことを特徴とする、被験者の乾癬性関節炎の治療方法。
- 前記miR−146a−5p阻害剤は配列番号5であることを特徴とする、請求項7に記載の使用。
- 前記miR−941阻害剤は配列番号4であることを特徴とする、請求項7に記載の使用。
- 被験者中の乾癬性関節炎の治療の有効性を判断する方法であって、
(a)前記治療の少なくとも一部を前記被験者に提供する前に、前記被験者から得られた第1サンプル中のmiR−146a−5p及びmiR−941からなる群から選択される少なくとも1つのmiRNAの発現レベルを測定するステップと、
(b)前記治療の少なくとも一部を前記被験者に提供した後に、前記被験者から得られた第2サンプル中の前記ステップ(a)の少なくとも一つの対応のmiRNAの発現レベルを測定するステップと、
を含み、
前記第1サンプル中の対応のmiRNAの発現レベルと比較した、前記第2サンプル中の少なくとも1つのmiRNAの発現レベルの低下は、前記治療が乾癬性関節炎に有効であることの指標となることを特徴とする、被験者中の乾癬性関節炎の治療の有効性を判断する方法。 - 前記第1サンプル及び前記第2サンプルはCD14+単球であることを特徴とする、請求項10に記載の方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862702551P | 2018-07-24 | 2018-07-24 | |
US62/702,551 | 2018-07-24 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020054336A true JP2020054336A (ja) | 2020-04-09 |
JP6997142B2 JP6997142B2 (ja) | 2022-02-03 |
Family
ID=67438641
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019136489A Active JP6997142B2 (ja) | 2018-07-24 | 2019-07-24 | 乾癬性関節炎の診断及び治療 |
Country Status (5)
Country | Link |
---|---|
US (2) | US11220712B2 (ja) |
EP (1) | EP3599288B1 (ja) |
JP (1) | JP6997142B2 (ja) |
CN (1) | CN110777199B (ja) |
TW (1) | TWI704927B (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112646876B (zh) * | 2021-01-11 | 2023-03-14 | 广东省中医院(广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院) | 用于银屑病诊断的miRNA及其应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009532392A (ja) * | 2006-04-03 | 2009-09-10 | サンタリス ファーマ アー/エス | antimiRNAアンチセンスオリゴヌクレオチドを含む医薬組成物 |
WO2010003420A2 (en) * | 2008-06-17 | 2010-01-14 | Gentofte Hospital | Treatment of psoriasis and related diseases by mirna modulation |
US20100202973A1 (en) * | 2007-05-18 | 2010-08-12 | Karolinska Institutet Innovations Ab | Microrna molecules associated with inflammatory skin disorders |
JP2010529847A (ja) * | 2007-06-14 | 2010-09-02 | ミルクス セラピューティクス アンパーツゼルスカブ | 標的rna活性の調節のためのオリゴヌクレオチド |
CN104278030A (zh) * | 2013-07-05 | 2015-01-14 | 上海交通大学医学院 | 小分子化合物Antagomir-31制备方法及应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2742148B1 (en) | 2011-08-11 | 2017-06-28 | Hummingbird Diagnostics GmbH | Complex sets of mirnas as non-invasive biomarkers for psoriasis |
-
2019
- 2019-07-11 CN CN201910623680.5A patent/CN110777199B/zh active Active
- 2019-07-19 US US16/516,663 patent/US11220712B2/en active Active
- 2019-07-23 EP EP19187927.9A patent/EP3599288B1/en active Active
- 2019-07-24 JP JP2019136489A patent/JP6997142B2/ja active Active
- 2019-07-24 TW TW108126131A patent/TWI704927B/zh active
-
2021
- 2021-11-26 US US17/535,880 patent/US11851708B2/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009532392A (ja) * | 2006-04-03 | 2009-09-10 | サンタリス ファーマ アー/エス | antimiRNAアンチセンスオリゴヌクレオチドを含む医薬組成物 |
US20100202973A1 (en) * | 2007-05-18 | 2010-08-12 | Karolinska Institutet Innovations Ab | Microrna molecules associated with inflammatory skin disorders |
JP2010529847A (ja) * | 2007-06-14 | 2010-09-02 | ミルクス セラピューティクス アンパーツゼルスカブ | 標的rna活性の調節のためのオリゴヌクレオチド |
WO2010003420A2 (en) * | 2008-06-17 | 2010-01-14 | Gentofte Hospital | Treatment of psoriasis and related diseases by mirna modulation |
CN104278030A (zh) * | 2013-07-05 | 2015-01-14 | 上海交通大学医学院 | 小分子化合物Antagomir-31制备方法及应用 |
Non-Patent Citations (3)
Title |
---|
IUBMB LIFE (2015) VOL.67, NO.12, PP.923-927, JPN6020043394, ISSN: 0004543760 * |
PLOS ONE (2007) VOL.2, NO.7, E610, PP.1-8, JPN6020043395, ISSN: 0004543761 * |
WADE S., ET AL.: "MIR-125A DECREASED IN PSA SYNOVIUM AND PERIPHERAL BLOOD CD14+ MONOCYTES AND CORRELATES TO JOINT ANGI", ANNALS OF THE RHEUMATIC DISEASES (2016) VOL.75, SUPPL.2, P.86 (OP0083), JPN6020043393, ISSN: 0004543759 * |
Also Published As
Publication number | Publication date |
---|---|
EP3599288A3 (en) | 2020-04-08 |
TW202019483A (zh) | 2020-06-01 |
US11851708B2 (en) | 2023-12-26 |
US20220090202A1 (en) | 2022-03-24 |
US20200032341A1 (en) | 2020-01-30 |
CN110777199A (zh) | 2020-02-11 |
US11220712B2 (en) | 2022-01-11 |
TWI704927B (zh) | 2020-09-21 |
EP3599288A2 (en) | 2020-01-29 |
JP6997142B2 (ja) | 2022-02-03 |
EP3599288B1 (en) | 2023-06-21 |
EP3599288C0 (en) | 2023-06-21 |
CN110777199B (zh) | 2023-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111961725B (zh) | 胰腺癌的检测试剂盒或装置以及检测方法 | |
EP2733219B1 (en) | Diagnostic miRNA markers for Alzheimer | |
TWI580788B (zh) | 用於檢測川崎病的方法及套組 | |
KR20190020649A (ko) | 역형성 림프종 키나아제(alk) 핵산 및 alk 융합 전사물의 혈장 기반 검출 및 암의 진단 및 치료에 있어 이의 용도 | |
KR20150109407A (ko) | miRNA-124 바이오마커 | |
US20210404002A1 (en) | Quantitative Algorithm for Endometriosis | |
EP2733220B1 (en) | Novel miRNA as a diagnostic marker for Alzheimer's Disease | |
EP3122905B1 (en) | Circulating micrornas as biomarkers for endometriosis | |
KR102505827B1 (ko) | 이식거부 및 면억억제 요법의 내성을 진단하기 위한 마이크로 리보핵산(miRNA)의 용도 | |
TWI682034B (zh) | 用於評估子宮內膜癌的發展風險或診斷子宮內膜癌的方法 | |
KR101828125B1 (ko) | 다발성 경화증에서의 진단 miRNA 프로파일 | |
JP6827067B2 (ja) | ループス腎炎の検出またはそのリスクを予測する方法およびその応用 | |
US11851708B2 (en) | Diagnosis and treatment of psoriatic arthritis | |
US20150045243A1 (en) | Mirnas as non-invasive biomarkers for diagnosis | |
US20140221506A1 (en) | Methods of Diagnosing Neuropathic Pain | |
RU2453606C2 (ru) | Способ расширенного скрининга предрасположенности к сердечно-сосудистым заболеваниям и биочип для осуществления этого способа | |
RU2625503C2 (ru) | Определение содержания GC-богатой последовательности генома (GC-ДНК) в составе циркулирующей внеклеточной ДНК плазмы периферической крови как способ определения уровня гибели клеток при беременности | |
TW202305146A (zh) | 利用微小核醣核酸檢測合併乾癬性關節炎及僵直性脊椎炎之血清陰性關節炎風險與發炎性腸炎引起的相關性背痛風險的方法及其應用 | |
KR102555878B1 (ko) | 하향조절된 mirna의 진단 및 치료를 위한 용도 | |
JP2024035040A (ja) | 分析方法、キット及び検出用デバイス | |
RU2771757C2 (ru) | Биомаркеры травматического повреждения головного мозга | |
WO2009157251A1 (ja) | 統合失調症の診断方法 | |
WO2022269607A1 (en) | A method for determining suitability of a subject to anti-tnf αlpha therapy | |
KR20230039740A (ko) | 인지 상태에 대한 바이오마커 | |
CN118139987A (zh) | 用于cfrna和cftna靶向ngs测序的组合物和方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20191119 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20201028 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201117 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210215 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210706 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210810 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20211214 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20211216 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6997142 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |